JP2014519911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519911A5 JP2014519911A5 JP2014513592A JP2014513592A JP2014519911A5 JP 2014519911 A5 JP2014519911 A5 JP 2014519911A5 JP 2014513592 A JP2014513592 A JP 2014513592A JP 2014513592 A JP2014513592 A JP 2014513592A JP 2014519911 A5 JP2014519911 A5 JP 2014519911A5
- Authority
- JP
- Japan
- Prior art keywords
- ecm
- composition
- thrombospondin
- interleukin
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 12
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 12
- 210000002744 extracellular matrix Anatomy 0.000 claims 12
- 210000004876 tela submucosa Anatomy 0.000 claims 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 claims 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- 102100032350 Protransforming growth factor alpha Human genes 0.000 claims 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 2
- 102100029529 Thrombospondin-2 Human genes 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 2
- 108010060887 thrombospondin 2 Proteins 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- FJLGEFLZQAZZCD-MCBHFWOFSA-N (3R,5S)-fluvastatin Chemical compound C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 FJLGEFLZQAZZCD-MCBHFWOFSA-N 0.000 claims 1
- 102100038778 Amphiregulin Human genes 0.000 claims 1
- 108010033760 Amphiregulin Proteins 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 claims 1
- 108700005376 Cartilage Oligomeric Matrix Proteins 0.000 claims 1
- 102100027473 Cartilage oligomeric matrix protein Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000003816 Interleukin-13 Human genes 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- 101150111584 RHOA gene Proteins 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 108010046722 Thrombospondin 1 Proteins 0.000 claims 1
- 102100036034 Thrombospondin-1 Human genes 0.000 claims 1
- 102100029524 Thrombospondin-3 Human genes 0.000 claims 1
- 102100029219 Thrombospondin-4 Human genes 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 210000002469 basement membrane Anatomy 0.000 claims 1
- -1 cervistatin Chemical compound 0.000 claims 1
- 229960003765 fluvastatin Drugs 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 229940076264 interleukin-3 Drugs 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 229960002797 pitavastatin Drugs 0.000 claims 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 108010060803 thrombospondin 3 Proteins 0.000 claims 1
- 108010060815 thrombospondin 4 Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491723P | 2011-05-31 | 2011-05-31 | |
| US61/491,723 | 2011-05-31 | ||
| US201261650911P | 2012-05-23 | 2012-05-23 | |
| US61/650,911 | 2012-05-23 | ||
| PCT/US2012/039416 WO2012166539A1 (en) | 2011-05-31 | 2012-05-24 | Compositions for preventing cardiac arrhythmia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014519911A JP2014519911A (ja) | 2014-08-21 |
| JP2014519911A5 true JP2014519911A5 (cg-RX-API-DMAC7.html) | 2015-06-18 |
Family
ID=47259771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513592A Pending JP2014519911A (ja) | 2011-05-31 | 2012-05-24 | 心不整脈を予防するための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8877224B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2713943A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014519911A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140029471A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012262539B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013030983A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2835858A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL229285B (cg-RX-API-DMAC7.html) |
| SG (1) | SG194881A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012166539A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8962324B2 (en) * | 2006-01-18 | 2015-02-24 | Cormatrix Cardiovascular, Inc | Method and system for treatment of biological tissue |
| US8257434B2 (en) | 2007-12-18 | 2012-09-04 | Cormatrix Cardiovascular, Inc. | Prosthetic tissue valve |
| US8679176B2 (en) | 2007-12-18 | 2014-03-25 | Cormatrix Cardiovascular, Inc | Prosthetic tissue valve |
| ES2553762T3 (es) * | 2009-02-18 | 2015-12-11 | Cormatrix Cardiovascular, Inc. | Composiciones y métodos para prevenir la arritmia cardiaca |
| JP2014533119A (ja) | 2011-05-27 | 2014-12-11 | コーマトリックス カーディオバスキュラー， インコーポレイテッドＣｏｒＭａｔｒｉｘ Ｃａｒｄｉｏｖａｓｃｕｌａｒ， Ｉｎｃ． | 細胞外マトリックス材料の弁導管及びその作製方法 |
| JP5902827B2 (ja) * | 2011-12-09 | 2016-04-13 | アセル，インコーポレイテッド | 止血装置 |
| BR112015014386A2 (pt) * | 2012-12-17 | 2017-09-26 | Cormatrix Cardiovascular Inc | dispositivo de distribuição de agente intramiocárdico e métodos relacionados |
| US9801910B2 (en) * | 2014-03-17 | 2017-10-31 | Ethicon, Inc. | Decellularized pleural matrix |
| CN111265719B (zh) | 2014-03-21 | 2023-01-10 | 匹兹堡大学-联邦高等教育体系 | 最终消毒的来自细胞外基质的水凝胶的制备方法 |
| CA3011294A1 (en) | 2016-01-13 | 2017-07-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vascular extracellular matrix hydrogel |
| CN106726009A (zh) * | 2017-03-06 | 2017-05-31 | 董念国 | 主动脉介入瓣制造方法 |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| WO2020219827A1 (en) * | 2019-04-24 | 2020-10-29 | Viadigm, Llc | Methods of tissue processing |
| US20220257665A1 (en) * | 2019-06-06 | 2022-08-18 | Novo Nordisk A/S | Application of antiarrhythmic agents to stem cell derived cardiomyocytes and uses thereof |
| JP2023514821A (ja) * | 2020-02-28 | 2023-04-11 | テキサス メディカル センター | 癒着阻止および組織治癒向上のための噴霧可能刺激応答性マイクロヒドロゲル |
| CN114569791B (zh) * | 2022-01-27 | 2022-08-30 | 浙江大学杭州国际科创中心 | 一种鱼鳔基心肌贴片的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387419A (en) * | 1988-03-31 | 1995-02-07 | The University Of Michigan | System for controlled release of antiarrhythmic agents |
| US5900433A (en) * | 1995-06-23 | 1999-05-04 | Cormedics Corp. | Vascular treatment method and apparatus |
| JP2006508773A (ja) * | 2002-12-05 | 2006-03-16 | 株式会社カルディオ | 生体適合性組織片およびその利用 |
| AU2003902037A0 (en) * | 2003-04-24 | 2003-05-15 | Mclachlan, Craig | Method for tissue growth |
| US7186214B2 (en) * | 2004-02-12 | 2007-03-06 | Medtronic, Inc. | Instruments and methods for accessing an anatomic space |
| US8568761B2 (en) * | 2005-07-15 | 2013-10-29 | Cormatrix Cardiovascular, Inc. | Compositions for regenerating defective or absent myocardium |
| AU2006292203A1 (en) * | 2005-09-21 | 2007-03-29 | Dask Technologies, Llc | Methods and compositions for organ and tissue functionality |
| US8303648B2 (en) * | 2006-04-25 | 2012-11-06 | Cook Medical Technologies Llc | Artificial venous valve containing therapeutic agent |
| WO2010042856A2 (en) * | 2008-10-09 | 2010-04-15 | The General Hospital Corporation | Tissue engineered myocardium and methods of production and uses thereof |
| US20100310629A1 (en) * | 2008-12-23 | 2010-12-09 | Gray Richard J | Intrapericardial antiarrhythmic delivery |
| ES2553762T3 (es) * | 2009-02-18 | 2015-12-11 | Cormatrix Cardiovascular, Inc. | Composiciones y métodos para prevenir la arritmia cardiaca |
| US20100239632A1 (en) * | 2009-03-23 | 2010-09-23 | Warsaw Orthopedic, Inc. | Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
| WO2011031301A2 (en) * | 2009-08-28 | 2011-03-17 | Mount Sinai School Of Medicine Of New York University | Intrapericardial delivery of periostin |
-
2012
- 2012-05-24 AU AU2012262539A patent/AU2012262539B2/en not_active Ceased
- 2012-05-24 KR KR20137031705A patent/KR20140029471A/ko not_active Withdrawn
- 2012-05-24 BR BR112013030983A patent/BR112013030983A2/pt not_active IP Right Cessation
- 2012-05-24 CA CA 2835858 patent/CA2835858A1/en not_active Abandoned
- 2012-05-24 WO PCT/US2012/039416 patent/WO2012166539A1/en not_active Ceased
- 2012-05-24 US US13/480,140 patent/US8877224B2/en not_active Expired - Fee Related
- 2012-05-24 JP JP2014513592A patent/JP2014519911A/ja active Pending
- 2012-05-24 SG SG2013083191A patent/SG194881A1/en unknown
- 2012-05-24 EP EP12793611.0A patent/EP2713943A4/en not_active Withdrawn
-
2013
- 2013-06-25 US US13/926,026 patent/US9060969B2/en active Active
- 2013-11-06 IL IL229285A patent/IL229285B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519911A5 (cg-RX-API-DMAC7.html) | ||
| Kajahn et al. | Artificial extracellular matrices composed of collagen I and high sulfated hyaluronan modulate monocyte to macrophage differentiation under conditions of sterile inflammation | |
| Létourneau et al. | IL-2–and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets | |
| Nuschke | Activity of mesenchymal stem cells in therapies for chronic skin wound healing | |
| TWI334443B (en) | Method of single cell culture of undifferentiated human embryonic stem cells | |
| Jiang et al. | Osteoimmunology in orthodontic tooth movement | |
| Leclerc et al. | Cell therapy of burns | |
| GB2470689A (en) | Differentiation of primate pluripotent stem cells to hematopoietic lineage cells | |
| JP2017525364A5 (cg-RX-API-DMAC7.html) | ||
| JP2006525995A5 (cg-RX-API-DMAC7.html) | ||
| CN102994448A (zh) | 一种体外扩增γδT细胞的方法 | |
| GB2433943A (en) | Cultivation of primate embryonic stem cells | |
| JP2007296371A5 (cg-RX-API-DMAC7.html) | ||
| EA201390981A1 (ru) | Разрушающаяся во рту таблетка | |
| JP2006514034A5 (cg-RX-API-DMAC7.html) | ||
| TW200916581A (en) | Paracrine signals from mesenchymal feeder cells and regulating expansion and differentiation of hepatic progenitors using same | |
| HK1202809A1 (en) | Mammalian fetal pulmonary cells and therapeutic use of same | |
| JP2013543760A5 (cg-RX-API-DMAC7.html) | ||
| US20150100115A1 (en) | Extracellular Matrix Prostheses for Treating Damaged Biological Tissue | |
| Vallés et al. | Modulation of the cross-talk between macrophages and osteoblasts by titanium-based particles | |
| ATE374628T1 (de) | Milchproteinbiofilm und verwendungen davon | |
| JP2014500263A5 (cg-RX-API-DMAC7.html) | ||
| JP2017136014A (ja) | Ｍ２様マクロファージ組成物の製造方法、およびｍ２様マクロファージ組成物原料 | |
| Maia et al. | In vitro evaluation of acellular dermal matrix as a three‐dimensional scaffold for gingival fibroblasts seeding | |
| WO2007008488A3 (en) | Stable quantitation and detection of immune response levels with non-zero background peptides |